PLYX Stock Forecast: Polaryx Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.32
−12.58% on the day

The median 12-month analyst price target for Polaryx Therapeutics, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$65.8M
Ticker Nerd rank
11/ 100
Median analyst target
$7.00
Analysts covering
4
Revenue$0.0
Operating income−$1.4M
Net income−$1.4M
Free cash flow−$1.4M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−25.4%
1M
−30.9%
From high
−96.2%
From low
0.0%
$1
$35
Range since 2 Feb 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Polaryx Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
11/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
64
Accruals
35
Revisions
30
Issuance
30
Quality
18
Growth
17
Volatility
4
Momentum
1

Value (64): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PLYX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLYX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 2 Feb 2026Adjusted close, US dollars
$0$10$20$30$40Apr 26Jul 26Oct 26PLYXHigh $10.00Median $7.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$6.00
Low
$7.00
Median
$10.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026Raymond JamesInitiatesStrong Buy$6.00
27 July 2026LUCID CAPITAL MARKETSInitiatesBuy$7.00
9 July 2026HC Wainwright & Co.InitiatesBuy$7.00
27 Feb 2026Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PLYX.

Market Radar

This page is one stock. Monday covers all of them.

PLYX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PLYX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

PLYX vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Apr 26Jul 26Oct 26PLYXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PLYX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
8.7×

Cheaper than 9% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−135.5%

Higher than 11% of US stocks

Return on assets
−64.9%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Polaryx Therapeutics, Inc. has a market value of $65.8M and an enterprise value of $57.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$6.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$5.8M.

  • Shares outstanding: 49.8M.

  • Polaryx Therapeutics, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

PLYX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PLYXPolaryx Therapeutics, Inc.$65.8M11
PMVPPMV Pharmaceuticals, Inc.$66.1M56
CRDFCardiff Oncology, Inc.$65.7M48
CINGCingulate, Inc.$65.6M25
GOSSGossamer Bio, Inc.$65.5M65
TNYATenaya Therapeutics, Inc.$65.3M50
MAIAMAIA Biotechnology, Inc.$67.3M40

Take a look at PLYX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Polaryx Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PLYX

What is the PLYX stock price forecast for 2026-2027?

The median 12-month analyst price target for Polaryx Therapeutics, Inc. is $7, with estimates ranging from $6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PLYX stock a buy right now?

Of the 4 analysts covering Polaryx Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Polaryx Therapeutics, Inc. 11 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLYX?

As at 21 Nov 2026, Polaryx Therapeutics, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (64 of 100).

Will PLYX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $7, and Ticker Nerd's factor model ranks Polaryx Therapeutics, Inc. 11 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PLYX stock forecast for 2030?

No analyst covering Polaryx Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $10 over the next 12 months.

What does Polaryx Therapeutics, Inc. do?

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare pediatric lysosomal storage disorders. Polaryx Therapeutics works on small molecule and gene therapy programs designed to address the underlying biology of severe inherited conditions, including neuronal ceroid lipofuscinoses, Krabbe disease, Tay-Sachs and Sandhoff diseases, and Niemann-Pick disease types A and B.

Company

About Polaryx Therapeutics, Inc.

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare pediatric lysosomal storage disorders. Polaryx Therapeutics works on small molecule and gene therapy programs designed to address the underlying biology of severe inherited conditions, including neuronal ceroid lipofuscinoses, Krabbe disease, Tay-Sachs and Sandhoff diseases, and Niemann-Pick disease types A and B. Its current portfolio emphasizes patient-friendly treatment approaches, including orally available small molecules and a gene therapy candidate, supporting its role in the rare disease drug development market. Headquartered in Paramus, New Jersey, and founded in 2014, Polaryx Therapeutics is positioned as a specialized biotechnology company addressing areas of high unmet medical need.

CEO Mr. Alex Yang J.D., L.L.M. · 2 employees · United States · https://polaryx.com